Fuente: PubMed "Cannabis" J Psychoactive Drugs. 2026 Jun 19:1-13. doi: 10.1080/02791072.2026.2685527. Online ahead of print.ABSTRACTGiven the increases in psychedelic use, we examined correlates of psychedelic use and use motives among US young adults. In 2025, adults ages 18-34 (n = 3,227; Mage = 26.38, ~50% past-month cannabis use by design) completed an online survey. Multivariable regression assessed sociodemographics, mental health, and adverse childhood events (ACEs) in relation to: (1) past-year psychedelic use; and (2) among those reporting lifetime use: (a) lifetime microdosing and (b) use motives. Lifetime and past-year psychedelic use were 27.7% and 11.9% (commonly psilocybin/amanita, MDMA, and LSD); 48.8% used only for nonmedical purposes. Of those reporting lifetime use, 26.5% ever microdosed. Correlates of use-related outcomes varied: (1) lifetime use: older, male (vs female), Black (vs White), metropolitan/urban (vs rural), more depressive symptoms and ACEs; (2) microdosing: not having children, more anxiety symptoms and ACEs; (3) higher expansion motives: male, White (vs Asian), more anxiety symptoms and ACEs; (4) higher mood/social enhancement motives: more depressive symptoms; and (5) higher symptom management motives: male, Hispanic, more depressive symptoms and ACEs. Despite half using exclusively for nonmedical purposes, mental health symptoms and ACEs were associated with use, microdosing, and higher use motives. Understanding the role of mental health across sociodemographic groups is necessary to address possible adverse outcomes.PMID:42318842 | DOI:10.1080/02791072.2026.2685527